News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Argenica Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Argenica’s latest HIE trial results show prolonged reduction in brain injury
Health & Biotech
Stock Insiders: Argenica progresses to Phase 2 clinical trial in stroke patients with ARG-007
Health & Biotech
Argenica secures significant non-dilutive funding for preclinical studies into newborn brain injury
Health & Biotech
Argenica confirms safety of ARG-007 in Phase-1 trial, makes preparations for Phase-2
News
Market Highlights: ASX to surge after strong rally on Wall Street, and 5 small caps to watch today
Health & Biotech
ASX Health Stocks: Partnership deals send Avecho shares flying this morning
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: If everything could just stop blowing up for a while, that’d be great.
News
ASX Small Caps Lunch Wrap: How many stolen monkeys does one man really need?
Health & Biotech
ASX Health Stocks: Argenica rockets by 30pc after showing potential breakthrough on Alzheimer’s
News
Top 10 at 10: These ASX health and biotech stocks have a spring in their step today
News
Market Highlights: Google’s embarrassing error, and 5 ASX small caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Argenica steps up dose in Phase 1 trial; Medlab gets blessing from UK regulator
News
Market Highlights: Thanksgiving, Binance’s $1bn lifeline, and 5 ASX small caps to watch on Friday
Health & Biotech
ASX Health Stocks: Argenica’s Phase 1 trial takes crucial step forward after drug safety confirmed
Health & Biotech
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
Health & Biotech
